Cargando…
Survival rate of ovarian cancer in Asian countries: a systematic review and meta-analysis
BACKGROUND: Ovarian cancer is amongst one of the most commonly occurring cancers affecting women, and the leading cause of gynecologic related cancer death. Its poor prognosis and high mortality rates can be attributed to the absence of specific signs and symptoms until advance stages, which frequen...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10276364/ https://www.ncbi.nlm.nih.gov/pubmed/37328812 http://dx.doi.org/10.1186/s12885-023-11041-8 |
_version_ | 1785060060454453248 |
---|---|
author | Maleki, Zahra Vali, Mohebat Nikbakht, Hossein-Ali Hassanipour, Soheil Kouhi, Aida Sedighi, Saman Farokhi, Roya Ghaem, Haleh |
author_facet | Maleki, Zahra Vali, Mohebat Nikbakht, Hossein-Ali Hassanipour, Soheil Kouhi, Aida Sedighi, Saman Farokhi, Roya Ghaem, Haleh |
author_sort | Maleki, Zahra |
collection | PubMed |
description | BACKGROUND: Ovarian cancer is amongst one of the most commonly occurring cancers affecting women, and the leading cause of gynecologic related cancer death. Its poor prognosis and high mortality rates can be attributed to the absence of specific signs and symptoms until advance stages, which frequently leads to late diagnosis. Survival rate of patients diagnosed with ovarian cancer can be used in order to better assess current standard of care; the aim of this study is to evaluate the survival rate of ovarian cancer patients in Asia. METHODS: Systematic review was performed on articles that were published by the end of August 2021 in five international databases, including Medline / PubMed, ProQuest, Scopus, Web of Knowledge, and Google Scholar. The Newcastle-Ottawa quality evaluation form was used for cohort studies to evaluate the quality of the articles. The Cochran-Q and I(2) tests were used to calculate the heterogeneity of the studies. The Meta-regression analysis was also done according to when the study was published. RESULTS: A total of 667 articles were reviewed, from which 108 were included in this study because they passed the criteria. Based on a randomized model, the survival rates of ovarian cancer after 1, 3 and 5 years were respectively 73.65% (95% CI, 68.66–78.64), 61.31% (95% CI, 55.39–67.23) and 59.60% (95% CI, 56.06–63.13). Additionally, based on meta-regression analysis, there was no relationship between the year of study and survival rate. CONCLUSIONS: The 1-year survival rate was higher than that of 3- and 5-year for ovarian cancer. This study provides invaluable information that can not only help establish better standard of care for treatment of ovarian cancer, but also assist in development of superior health interventions for prevention and treatment of the disease. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12885-023-11041-8. |
format | Online Article Text |
id | pubmed-10276364 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-102763642023-06-18 Survival rate of ovarian cancer in Asian countries: a systematic review and meta-analysis Maleki, Zahra Vali, Mohebat Nikbakht, Hossein-Ali Hassanipour, Soheil Kouhi, Aida Sedighi, Saman Farokhi, Roya Ghaem, Haleh BMC Cancer Research BACKGROUND: Ovarian cancer is amongst one of the most commonly occurring cancers affecting women, and the leading cause of gynecologic related cancer death. Its poor prognosis and high mortality rates can be attributed to the absence of specific signs and symptoms until advance stages, which frequently leads to late diagnosis. Survival rate of patients diagnosed with ovarian cancer can be used in order to better assess current standard of care; the aim of this study is to evaluate the survival rate of ovarian cancer patients in Asia. METHODS: Systematic review was performed on articles that were published by the end of August 2021 in five international databases, including Medline / PubMed, ProQuest, Scopus, Web of Knowledge, and Google Scholar. The Newcastle-Ottawa quality evaluation form was used for cohort studies to evaluate the quality of the articles. The Cochran-Q and I(2) tests were used to calculate the heterogeneity of the studies. The Meta-regression analysis was also done according to when the study was published. RESULTS: A total of 667 articles were reviewed, from which 108 were included in this study because they passed the criteria. Based on a randomized model, the survival rates of ovarian cancer after 1, 3 and 5 years were respectively 73.65% (95% CI, 68.66–78.64), 61.31% (95% CI, 55.39–67.23) and 59.60% (95% CI, 56.06–63.13). Additionally, based on meta-regression analysis, there was no relationship between the year of study and survival rate. CONCLUSIONS: The 1-year survival rate was higher than that of 3- and 5-year for ovarian cancer. This study provides invaluable information that can not only help establish better standard of care for treatment of ovarian cancer, but also assist in development of superior health interventions for prevention and treatment of the disease. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12885-023-11041-8. BioMed Central 2023-06-16 /pmc/articles/PMC10276364/ /pubmed/37328812 http://dx.doi.org/10.1186/s12885-023-11041-8 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Maleki, Zahra Vali, Mohebat Nikbakht, Hossein-Ali Hassanipour, Soheil Kouhi, Aida Sedighi, Saman Farokhi, Roya Ghaem, Haleh Survival rate of ovarian cancer in Asian countries: a systematic review and meta-analysis |
title | Survival rate of ovarian cancer in Asian countries: a systematic review and meta-analysis |
title_full | Survival rate of ovarian cancer in Asian countries: a systematic review and meta-analysis |
title_fullStr | Survival rate of ovarian cancer in Asian countries: a systematic review and meta-analysis |
title_full_unstemmed | Survival rate of ovarian cancer in Asian countries: a systematic review and meta-analysis |
title_short | Survival rate of ovarian cancer in Asian countries: a systematic review and meta-analysis |
title_sort | survival rate of ovarian cancer in asian countries: a systematic review and meta-analysis |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10276364/ https://www.ncbi.nlm.nih.gov/pubmed/37328812 http://dx.doi.org/10.1186/s12885-023-11041-8 |
work_keys_str_mv | AT malekizahra survivalrateofovariancancerinasiancountriesasystematicreviewandmetaanalysis AT valimohebat survivalrateofovariancancerinasiancountriesasystematicreviewandmetaanalysis AT nikbakhthosseinali survivalrateofovariancancerinasiancountriesasystematicreviewandmetaanalysis AT hassanipoursoheil survivalrateofovariancancerinasiancountriesasystematicreviewandmetaanalysis AT kouhiaida survivalrateofovariancancerinasiancountriesasystematicreviewandmetaanalysis AT sedighisaman survivalrateofovariancancerinasiancountriesasystematicreviewandmetaanalysis AT farokhiroya survivalrateofovariancancerinasiancountriesasystematicreviewandmetaanalysis AT ghaemhaleh survivalrateofovariancancerinasiancountriesasystematicreviewandmetaanalysis |